MicroRNA (miR)-106a was involved in the tumorigenesis and highly expressed in gastric cancer. Required apatinib resistance greatly limits its efficacy in patients. Thus, the aim of the present study was to investigate the potential role of miR-106a-3p in gastric cancer cells with apatinib-resistance.
Background
Gastric cancer remains one of the most common cause of cancer death in humans worldwide. Gastric cancer seriously affects the survival rate and life condition of patients [1] . In clinical studies, apatinib is safe and efficient in the treatment of gastric cancer, which inhibits angiogenesis in cancer tissues by highly selectively competing for cellular binding site of ATP (adenosine triphosphate) in VEGFR-2 (Vascular endothelial growth factor receptor 2) [2, 3] . However, gastric cancer cells would acquire the phenotype of drug-resistant continuously exposed to chemotherapy. The occurrence of drug-resistant cells was related to some signaling pathways. For example, the apatinib resistance of gastric carcinoma could be induced by the oncogene, dual-specificity phosphatase-1, via the activation of MAPK [4] .
MicroRNA (miRNA) is involved in post-transcriptional regulation of DNA by binding to the 3'UTR region of the transcript sequence [5] . MiRNA-106a-3p (MiR-106a-3p) belongs to one of poorly conserved microRNA family members by Targetscan6.2. Even so, its effects cannot be neglected in gastric cancer as a circulatory oncogenic miRNA, the upregulation of miR-106a appeared in many cancers, especially stomach cancer. Furthermore, the study has found that the expression of miR-106a in gastric cancer tissues have a close relationship with the size, stage, and progression of tumor. It is still elusive how miR-106a exerts its functions in the progression of the apatinib resistance in gastric carcinoma [6] . Glutathione S-transferase p (GST-p), transports toxicant from tumor and mediates drug-resistant cell [7] . Multidrug resistance-associated protein 1 (MRP1) decreases cellular drug concentration [8] . The ATP-binding cassette transporters P-glycoprotein/ABCB1 transport multiple drugs across membranes [9] . The signal of cytokines from the membrane is transferred into cytoplasm by activation of signal transduction pathways, in the process of which (Janus-activated kinase) JAK2/signal transducer and activator of transcription 3 (START3) pathway is widely involved. Continuous activation of JAK2/START3 pathway could cause the aberrant proliferation and vicious transformation of cells and widely participate in the development of malicious cancer [10, 11] . The SOCS system could negatively regulate JAK/STAT system signal transduction. SOCS, suppressor of cytokine signaling, was characterized by the presence of a C-terminal SOCS box and a central SH2 domain [12] . SOCSbox-containing proteins probably function as E3 ubiquitin ligases and mediate the degradation of proteins associated with their N-terminal regions by NCBI. Some miRNA targeted SOCS gene, and then modulated STAT3 pathway [13] . MiR-106a as a vital oncogenic miRNA regulated the expression of many proteins involved in physiological processes in tumorigenesis [14] . Thus, the study focused on the role of miR-106a-3p in the apatinib resistance of gastric cancer, then discussed the potential biological mechanisms of apatinib resistance in gastric cancer.
Material and Methods

Cell culture
Human gastric cancer cell line including SGC-7901 and BGC-823 were purchased from the Cell Bank of Chinese Academy of Science (Shanghai, China). The cells were seeded into cell culture plate with RPMI-1640 medium containing 10% fetal bovine serum (FBS), 100 mg/L streptomycin, and 100 U/mL penicillin, and put into an incubator with 5% CO 2 at 37°C (FBS, RPMI-1640, streptomycin, penicillin; Gibco, USA).
Cell line of apatinib-resistance
SGC-7901/BGC-823 cells of ogarithmic phase were respectively treated with apatinib at the concentration of 0.001 μg/mL for 48 hours. Then, the refresh RPMI-1640 medium was replaced for subsequent culture. Cells of ogarithmic phase without evident death, were continuously cultured by gradually increasing the concentration of apatinib. Finally, cells that could survive stably at 1 μg/mL of apatinib, were regarded as drug-resistant SGC-7901 or BGC-823 (namely SGC-7901-AR, BGC-823-AR).
Plasmids, miRNA, and cell transfection
MiR-106a-3p mimic and corresponding negative control (miR-106a-3p NC), and miR-106a-3p inhibitor and corresponding negative control were purchased from GenePharma (Shanghai, China). The ShRNA plasmid vector anti-SOCS2, SOCS4 or SOCS5 were constructed by GenePharma (Shanghai, China), and referred as ShRNA-SOCS2, ShRNA-SOCS4, and ShRNA-SOCS5 respectively. The plasmid and oligonucleotide were transfected into cells by Lipofectamine 2000 reagent (Invitrogen, USA). Then, the cells were continuously cultured for 48 hours.
Real-time quantitative polymerase chain reaction (RT-qPCR)
Total RNA was extracted by TRIzol reagent (Invitrogen, USA). Then, the concentration of total RNA was measured by ultraviolet spectrophotometer. RNA was reverse transcribed into cDNA in the miScript Reverse Transcription Kit (TaKaRa, Japan) according to the manufacturer's instructions. Small RNA, U6, was used as a reference gene.
Cell Counting Kit-8 (CCK-8)
The cells were inoculated into 96-well plates and cultured for 24 hours. Next, Cell Counting Kit-8 (CCK8) solution (KeyGen, Nanjing, China) was added, and the cells were continually cultured for 4 hours in the incubator. The absorbance was detected by microplate reader (Bio-Rad, USA).
Western blot
The cells transfected for 48 hours were cleaved using RIRP Lysis Buffer (Thermo Fisher Scientific). Then, the supernatant was collected after centrifugation 4 times at 14 000 rpm for 15 minutes. The protein concentration was detected by bicinchoninic acid (BCA) kit (Bio-Rad, USA). The target protein was separated by SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis) and transferred into PVDF (polyvinylidene difluoride) membrane overnight. After the blots were sealed using 10% skim milk, the primary antibody was used to hybridize with the target protein overnight at 4°C (anti-MRP1, 1: 1000; anti-GST-p, 1: 2000; anti-ABCB1, 1: 1000; anti-GAPDH, 1: 5000; anti-SOCS2, 1: 1000; anti-SOCS4, 1: 1000; anti-SOCS5, 1: 1000; anti-p-JAK2, 1: 2000; anti-JAK2, 1: 2000; anti-p-STAT3, 1: 2000; anti-STAT3, 1: 2000; Thermo Fisher Scientific). Subsequently, the blots were incubated with horseradish peroxidase conjugated secondary antibody (1: 10 000) after washing in TBST. We used an ECL (enhanced chemiluminescence) kit (Abcam, USA) developed the blots.
Luciferase reporter assay SOCS2, SOCS4, or SOCS5 Luciferase reporter plasmid were constructed by GenePharma (Shanghai, China), the 3'UTR site of which was constructed downstream of the luciferase gene. WT SOCS was defined by the 3'UTR site binding to miR-106a-3p, while MUT SOCS was defined by the binding domain of 3'UTR where all base mutant occurred. SOCS2, SOCS4, or SOCS5 Luciferase reporter plasmid (wild type [WT] or mutant [MUT]) and miR-106a-3p NC or miR-106a-3p mimic were cotransfected into SGC-7901 cells using Lipofectamine 2000 according to manufacturer's protocols. The transfection effects were detected after 48 hours.
Statistical analysis
Multiple comparison was analyzed by ANOVA. The post t-test was used for pairwise comparison. The statistical analysis of experimental data was performed using Prism. P<0.05 was considered to indicate statistically significant difference.
Results
MiR-106a-3p inhibitor reduced SGC-7901 resistance to apatinib RT-qPCR was used to detect the miR-106a-3p levels. The miR-106a-3p levels presented significant increase in SGC-7901-AR and BGC-823-AR ( Figure 1A ). There were higher levels of miR-106a-3p in SGC-7901 cells compared to BGC-823 cells. MiR-106a-3p inhibitor significantly decreased the expression of miR-106a-3p in SGC-7901 and SGC-7901-AR respectively compared to miR-inhibitor-NC group. (Figure 1B, 1C) . Furthermore, the cell viability was assessed by CCK8 assay. miR-106a-3p inhibitor significantly increased the suppression of apatinib to SGC-7901-AR cells ( Figure 1D ). Western blot was used to detect the expression of drug-resistant related protein. The expression of GST-p and ABCB1 were significantly decreased in SGC-7901-AR by miR-106a-3p, while MRP1 levels had no obvious changes (Figure 1E, 1F) .
MiR-106a-3p targeted relevant genes of SOCS family
The miR-106a-3p levels were significantly increased by miR mimic in SGC-7901 and SGC-7901-AR cells (Figure 2A, 2B ). Targetscan6.2 was used to detect the relevant target miRNA. The binding sites of SOCS 3'UTR and miR-106a-3p, and the mutant sites were shown in Figure 2C , 2E, 2G. Luciferase reporter assay showed that the group SOCS 3'UTR WT+ miR-106a-3p mimic, presented reduced luciferase activity ( Figure 2D, 2F, 2H) . Thus, SOCS2, SOCS4, and SOCS5 were target genes of miR-106a-3p.
MiR-106a-3p inhibitor decreased the relevant gene expression of SOCS family
MiR-106a-3p inhibitor significantly increased the expression of SOCS2, SOCS4, and SOCS5 ( Figure 3A) . ShRNA-SOCS significantly decreased the expression of corresponding SOCS (Figure 3B, 3C) .
Sh-SOCS reversed the effect of miR-106a-3p inhibitor to p-JAK2, p-STAT3 and cell viability
MiR-106a-3p inhibitor significantly reduced the phosphorylation levels of JAK2 and STAT3, while Sh-SOCS significantly reversed the effects ( Figure 4A) . The cell viability also presents this effect ( Figure 4B ). 
Conclusions
Gastric cancer is a malignant tumor originating from gastric mucosa epithelium. Apatinib resistance in cancer cells severely limited the clinical application of apatinib. This study showed that miR-106a-3p affected the resistance of gastric cancer cell to apatinib in vitro. The mechanism involved in the process was that miR-106a-3p targeted the genes of SOCS family to induce apatinib resistance in gastric cancer and JAK/STAT also played a vital role and could help us to understand how miRNA exerts functions in gastric cancer cell resistance to apatinib.
MiR-106a-3p inhibitor suppressed the gastric cancer cell viability and reduced drug-resistant related proteins expression including GST-p and ABCB1. However, the expression of MRP1 presented no significant changes. The demethylation of miRNA promoter region mediated multi-drug resistance by targeting drug-resistant related ABC transporters including ABCB1 and ABCC5 [15] . A previous study showed that miR-508-5p could combine the 3'UTR region of ABCB1 and inhibited its levels to modulate multi-drug resistance in gastric cancer [16] . 
